Intervention

[18F]NAV4694

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 3 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials3

Recruiting0

Common conditions4

Lead sponsors shown1

Clinical trials

3 shown

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem HistopathologyNCT01886820 · 2013-06-01

UNKNOWN

Beta-Amyloid Imaging With [18F]NAV4694 PET in Predicting Progression to AD in Subjects MCINCT01812213 · 2013-03-01

TERMINATED

Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's DiseaseNCT01680588 · 2012-08-01

UNKNOWN

Common conditions

Alzheimer Disease1 Alzheimer's Disease1 Dementia1 Mild Cognitive Impairment1

Leading sponsors

Navidea Biopharmaceuticals 3

Trial status mix

UNKNOWN2

TERMINATED1

Phase mix

PHASE22

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.